Transcript Ewing Marion Kauffman Foundation

Mid-America Healthcare
Investors Network
- A Call to Action
© 2007 by the Ewing Marion Kauffman Foundation. All rights reserved.
“Every individual that we can
inspire, that we can guide, that we
can help to start a new company,
is vital to the future of our
economic welfare.”
— Ewing Kauffman
Stanford Biodesign Program
needs invent
med tech patent
license collaborate
cost effective
surgical innovation
license Stanford
FDA discovery
technology transfer
ethics & policy prototype reimbursement
specialty innovation teamwork outcomes
Mission
To develop leaders in biomedical
technology innovation
Educate. Collaborate. Innovate.
biodesign
Program in Biodesign
invention &
discovery
technology
transfer
education
ethics &
policy
A repeatable training process…
innovation knowledge and skills
Biodesign
BiodesignInnovation
InnovationFellowships
Fellowship
‘07-08 White Team: Anesthesia
Fogarty
Fellow
Grube
Fellow
David Boudreault Marie Johnson,
MD
PhD
St. Louis U
U of Minnesota
Lucile Packard
Fellow
Nandan Lad,
MD, PhD
Chicago Medical
Lucile Packard
Fellow
Beverly Tang,
PhD
Stanford
3 months clinical immersion…
Clinical Immersion/ Partnering with Departments
Identify at least 200 needs…
biodesign
Select the top needs to pursue…
Go for quantity of ideas…
NEED
CONCEPT
NEED
CONCEPT
NEED
CONCEPT
NEED
NEED
NEED
NEED
CONCEPT
CONCEPT
NEED
CONCEPT
CONCEPT
NEED
NEED
CONCEPT
CONCEPT
NEED
CONCEPT
NEED
NEED
CONCEPT
NEED
CONCEPT
biodesign
J. Abele, C. Alferness, P. Arensdorf, P. Auerbach, D. Auth, M. Baker, J. Bakker,
L. Barish, A. Belson, M. Berman, A. Bianchi, N. Blevins, L. Bottorff, K. Bowsher,
R. Buyan, B. Byers, J. Capek, M. Carusi, T. Chou, K. Connors, B. Constantz, R.
Croce, R. Curtis, M. Cutkosky, M. Dake, A. de Bord, M. Deem, J. Delagardelle,
D. Donohoe, D. Echt, D. Feigal, R. Ferrari, F. Fischer, R. Fisher, T. Fogarty, G.
Foster, J. Garfinkle, M. Garrison, J. Geriak, G. Gershony, H. Gifford, J. Gill, J.
Gold, J. Gordon, G. Graham, J. Green, J. Grossman, E. Grube, D. Gruenfeld, L.
Guterman, S. Hamade, W. Hawkins, M. Hendricksen, J. Hickey, T. Hinohara, R.
Hirsch, E. Hlavka, D. Hoffmeister, L. Hogle, H. Holstein, M. Horsewski, S.
Hossainy, K. Im, M. Imran, F. Ingle, P. Jackson, J. Jacobs, W. Jaeger, R. Jaffe, J.
Joye, S. Jwanouskos, A. Kaganov, D. Kelley, T. Kelley, K. Kelley, F. Khosravi, G.
Kilman, T. Kohler, E. Koskinas, M. Lachman, J. Lacob, G. Lambrecht, T.
Lamson, J. Lasersohn, S. Latterman, T. Lefteroff, M. Lesh, A. Macfarlane, W.
Maloney, J. Mandato, J. Maroney, D. Mauney, A. May, M. Mayer, C. McGlynn, L.
Michael, T. Mills, N. Mourlas, D. Murphy-Chutorian, J. Nehra, C. Nelson, W.
New, S. Oesterle, J. Onopchenko, M. Paganini, J. Palmaz, O. Palmer, T. Kim
Parnell, R. Perkins, T. Petersen, D. Piacquad, H. Plain, M. Raab, G. Rao, A.
Rasdal, R. Reiss, G. Robertson, D. Roeder, E. Rogers, S. Rowinski, G. Rubin,
S. Salmon, W. Samson, J. Schox, M. Selmon, J. Shapiro, J. Shay, T. Simons, J.
Simpson, Y. So, F. St. Goar, B. Starling, B. Stern, M. Sugarman, R. Sutton, J.
Swick, R. Tabibiazar, K. Talmadge, L. Tannenbaum, R. Thomas, S. Toyloy, S.
Turnbull, J.S. Uy, B. Vale, S. Van Bladel, C. Vidal, M. Wan, K. Wasserstein, K.
Widder, A. Will, J. Wilson, S. Wolf, T. Wollaeger, P. Young, R. Zider…& others
Real-World Mentors
Biodesign Fellow, Student & Alumni Start-Ups
SPIRACOR
Biodesign Year
Clinical Status
Business Status
1
OUS, US
Acquired
2
OUS, US
Series C
1
OUS, US
Series B
1
OUS, US
Acquired
4
Pre-Trial
Series A
6
Pre-Trial
Series A
4
Pre-Trial
Series A
7
Pre-Trial
SBIR Ph. 1
7
Pre-Trial
SBIR Ph. 1
7
Pre-Trial
Series A
biodesign
‘01 Fellows:
Nick Mourlas
Chris Eversull
Our real product
technology
transfer
Tech Transfer
biodesign
OTL
biodesign
Stanford Medical Device Invention Disclosures & Licenses
2000 to 2006
70
62
60
53
49
50
49
39
40
Disclosures
Licenses
30
30
20
18
9
10
2
4
2
5
3
3
0
2000
2001
2002
2003
2004
2005
2006
biodesign
Disclosures and licensing
Preliminary and confidential
Erik Pineiro, PhD
Karolinska Institute
Potential contribution of Biodesign
- The great increase in number of disclosures
with the OTL almost exactly coincides with the
start of the Medical Device Network (later to
become Biodesign)
- As the number of “active participants: (i.e.,
speakers, directors, teachers…) increases, the
number of disclosures increase.
Preliminary and confidential
Erik Pineiro, PhD
Karolinska Institute
Biodesign Corporate Sponsors
biodesign
Biodesign Venture Sponsors
Montreux Equity Partners
Advanced Technology Ventures
New Enterprise Associates
Alloy Ventures
New Leaf Venture Partners
Cytyc Corporation
ONSET Ventures
Delphi Ventures
Prospect Venture Partners
DeNovo Ventures
Sanderling Ventures
Frazier Healthcare Ventures
Split Rock Partners
Interwest Partners
Three Arch Partners
Kleiner, Perkins, Caufield &
US Venture Partners
Byers
Versant Ventures
Kearny Ventures
Mohr Davidow Ventures
biodesign
Innovative Excellence: An
Academic Model to Bridge the
Valley of Death
February 26, 2009
Scott Weir, PharmD, PhD
Director,
Institute for Advancing Medical Innovation
Institute for Advancing Medical Innovation
• Partnership with Ewing Marion Kauffman Foundation
» $8.1 million grant from Kauffman Foundation
» $8.1 million matching grant from University of Kansas
Endowment Association
• Mission
» Support commercialization through the discovery and
advancement of medical innovations and foster the
development of drug discovery, drug delivery, and
bioengineering entrepreneurs who can contribute to
economic growth
Why KU?
• University of Kansas School of Pharmacy ranked No. 1
» NCI formulation contract: 7 of 19 drugs from NCI’s
Developmental Therapeutics pipeline formulated by KU
» “Father of Physical Pharmacy”, Dr. Higuchi
• Medicinal Chemistry Program Strengths
» Chemical Methodologies and Library Development Center
» Specialized Chemistry Center *
» Center for Cancer Experimental Therapeutics COBRE
• Drug Delivery
» Pharmaceutical Chemistry Distinguished Professors
• Dr. Stella, Dr. Borchardt, Dr. Middaugh
• Biotechnology Innovation and Optimization Center
• KU Center for Technology Commercialization
* NIH Roadmap Initiative
Why KU?
• University of Kansas Cancer Center
» #1 priority for KU
» Vision to become number one academic generator of drugs
for treatment, prevention and control of cancer
• Office of Therapeutics, Discovery & Development
» Implements best practices from industry into academia to
foster commercialization in a quicker timeframe
• Established National and Regional Partnerships
» Stowers Institute for Medical Research; Leukemia &
Lymphoma Society; Institute for Pediatric Innovation;
Children’s Mercy Hospital; Kansas State University; Mayo
Clinic Comprehensive Cancer Center; Kansas Bioscience
Authority; Kansas Technology Enterprise Corporation
Institute for Advancing Medical Innovation
Novel Drugs &
Drug Targets
Drug Products &
Delivery
Platforms
Drug
Discovery
Research
Drug
Delivery
Research
Biomaterials
& Medical
Devices
BioEngineering
Research
Drug-Device
Combination
Products
Integrated
Bio-Engineering
& Drug Research
Training the Next Generation
Of Medical Innovators
Advance Medical Innovations To Commercialization
IAMI: Collaborative Models
Partnerships
• Goal: assist academic, industry and philanthropic
collaborators to advance medical innovations
• Philanthropic Partnerships
» Leukemia & Lymphoma Society
• $1.5 million in current funded projects
• Industry Partnerships
» Institute for Pediatric Innovation
• Partnership with Beckloff Associates,
Pediatric Hospital Consortium
• POC funding for 2 projects with IPI
• Academic Partnerships
» Scripps Research Institute
» The Cancer Prevention Program at the Mayo Clinic
Comprehensive Cancer Center
IAMI: Opportunities
Innovation Fellow Training and Education
Program
• Prepare graduate and postdoctoral students for careers in
development and commercialization of medical
innovations
• Fellows develop skills to successfully work in multidisciplinary environments and commercialize medical
innovations
• Curriculum includes academic and experimental focus
• Opportunities to participate in Kauffman Fellows program
activities
• Fellowships for 10 graduate students and 4 post-docs
IAMI: Opportunities
Proof of Concept Funds
• Funding to support proof of concept for outstanding
projects; focus on balanced portfolio
• Project Eligibility
» Clinical applications including: disease diagnosis, treatment
prevention and control
» Novel drug target, drug, product, drug delivery platform
technology, biomaterial, medical device, and drug-device
» KU intellectual property, sole inventors or co-inventors
• Funding Mechanisms
» RFP process annually
» Ad hoc funding mechanism throughout the year
IAMI: Opportunities
Proof of Concept Funds
• Funding typically ranges from $50K-$100K per project
• Funding is milestone driven, i.e., to advance project from
one decision point to the next
• Funding Process
» Application template
» Project plan including overall objectives, go no/go decision
points, specific studies or experiments, cost and timing
» Principal Scientist and Project Director required to make joint
presentation to Board
» Proposals vetted through IAMI Leadership Team prior to
submission to IAMI Advisory Board for consideration
» IAMI Industry Advisory Board reviews and approves funding
• Quarterly progress reports required
Final Points
Institute for Advancing Medical Innovation
• Completely integrated institute to foster advancement of
novel drug and drug targets, drug products, drug delivery
platform technologies, biomaterials, medical devices, and
drug-device combination products
• Includes program that incorporates training of graduate
and post-doc fellows in project management with realworld applications
• Unique program unlike anywhere else in the world
Mission
To help individuals attain
economic independence by
advancing educational
achievement and
entrepreneurial success.
© 2007 by the Ewing Marion Kauffman Foundation. All rights reserved.
New Firms and U.S. Economic Growth
600,000 new firms
per year
Of which 1,000
are high-growth
Equaling 1/3 of total
economic growth
Or 1% growth
each year
$
© 2007 by the Ewing Marion Kauffman Foundation. All rights reserved.
© 2007 by the Ewing Marion Kauffman Foundation. All rights reserved.
Focus on Founders
& Firm Creation
© 2007 by the Ewing Marion Kauffman Foundation. All rights reserved.
New Kauffman Programs

Kauffman Postdoc Fellows…the Kauffman 12

Kauffman Entrepreneur Fellows (incubators)

ExploraMed

The Foundry

PureTech Ventures

Kauffman Pediatric Innovation Fellows

Kauffman Singapore Scholars
© 2007 by the Ewing Marion Kauffman Foundation. All rights reserved.
Why is Kauffman Focusing on Postdocs?
“The critical role that scientists play in our
economy is compromised because faculty,
graduate students and postdocs do not
have a base level understanding of
commercialization to empower them to
recognize and advance their own
innovations.”
Lesa Mitchell, VP, Kauffman Advancing Innovation
© 2007 by the Ewing Marion Kauffman Foundation. All rights reserved.
Postdoctoral Researchers – a Quandary
The Promise

Postdocs are vital to the
scientific and clinical research
engine

They are 1st authors on 43% of
research papers (Science)

Many grants to PI’s are based
on postdoc research, postdocs
do bulk of research grant
writing
© 2007 by the Ewing Marion Kauffman Foundation. All rights reserved.
The Challenge



Postdocs are tied to the lab
bench, rarely get exposure to
entrepreneurship and
translational research
education on campus
Their PI often can’t evaluate
their own research for
commercial/translational
potential
1 of 10 postdocs seeking an
academic career get a faculty
position, yet many postdocs
struggle with making the
transition to industry (NPA)
Innovation Ecosystem
Open Collaborations
Faculty-Firm-Not for Profit Consulting/
Sponsored Research
© 2007 by the Ewing Marion Kauffman Foundation. All rights reserved.
Kauffman Postdoctoral Entrepreneur Fellowship







One year full support
PI agrees to <20 hours/week release time from bench
Evaluate and develop commercialization plan for
postdoc/lab’s research
Dedicated business mentor
Customized industry internship (venture firm, startup)
Entrepreneurship immersion workshops at Kauffman
Access to broader Kauffman network (investors, etc.)
Objective: train tomorrow’s scientific/clinical founders
© 2007 by the Ewing Marion Kauffman Foundation. All rights reserved.
A unique time for midwest life sciences

KU



Alignment of university leadership with talent & funding
A shift in approach to licensing, sponsored research
Other regional efforts



U Minn medical device center
Northwestern Univ “translational” bioengineering
Coulter Foundation translational research seed grant programs
at U Mich and Wisconsin
© 2007 by the Ewing Marion Kauffman Foundation. All rights reserved.
A Call to Action

We need you!




Teaching in courses, seminars
Mentoring & Coaching (students and faculty)
Advising
 Policy (IP, consulting, conflict of interest)
 Tech transfer
Why get involved?
 Relationships
 Increased & higher quality deal flow over long term
© 2007 by the Ewing Marion Kauffman Foundation. All rights reserved.
© 2007 by the Ewing Marion Kauffman Foundation. All rights reserved.